Skip to Content

Join the 'Ecallantide' group to help and get support from people like you.

Ecallantide News

FDA Approves Expanded Use of Kalbitor for the Treatment of HAE to Patients 12 Years of Age and Older

Posted 7 Apr 2014 by

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Kalbitor (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older. With this approval, KALBITOR is the first ...

Ask a Question

Further Information

Related Condition Support Groups

Hereditary Angioedema

Related Drug Support Groups


Ecallantide Patient Information at